Celcuity (CELC)

• Market cap: $419M
• 1 day: -1.25%
• 5 days: 0.27%
• 1 month: 9.59%
• 3 months: -5.46%
• 6 months: -30.14%
• Year to date: -15.61%
• 1 year: -29.74%
• 5 years: 84.36%
• 10 years: -22.46%
• Sector: Healthcare
• Industry: Biotechnology

About: Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Employees: 87

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

22,800% more call options, than puts

Call options by funds: $229K | Put options by funds: $1K

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

31% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 29

0.76% more ownership

Funds ownership: 81.08% [Q3] → 81.83% (+0.76%) [Q4]

10% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 21

2% less funds holding

Funds holding: 105 [Q3] → 103 (-2) [Q4]

11% less capital invested

Capital invested by funds: $450M [Q3] → $402M (-$47.7M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $27 144% upside
• Avg. target: $28 153% upside
• High target: $29 162% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Needham Gil Blum 18% 1-year accuracy 29 / 158 met price target	162% upside $29	Buy Reiterated	11 Apr 2025
HC Wainwright & Co. Swayampakula Ramakanth 28% 1-year accuracy 54 / 192 met price target	144% upside $27	Buy Reiterated	1 Apr 2025